-
Publication Venue For
-
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103.
2023
-
Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma..
22:112-122.
2023
-
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma..
21:762-774.
2022
-
Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation..
21:448-459.
2022
-
HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study..
21:217-226.
2022
-
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers..
20:2240-2249.
2021
-
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors..
20:1988-1995.
2021
-
Salting the Soil: Targeting the Microenvironment of Brain Metastases..
20:455-466.
2021
-
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis..
20:296-306.
2021
-
Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance..
20:85-95.
2021
-
A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer..
19:2516-2527.
2020
-
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib..
19:2146-2154.
2020
-
The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor..
19:1395-1405.
2020
-
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors..
19:1210-1217.
2020
-
Respiratory Capacity and Reserve Predict Cell Sensitivity to Mitochondria Inhibitors: Mechanism-Based Markers to Identify Metformin-Responsive Cancers..
18:693-705.
2019
-
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105..
17:2248-2256.
2018
-
Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma..
17:858-868.
2018
-
Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer..
17:464-473.
2018
-
Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer..
16:914-923.
2017
-
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer..
15:2894-2904.
2016
-
Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth..
15:1344-1352.
2016
-
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer..
14:2677-2686.
2015
-
Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors..
14:2143-2153.
2015
-
PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer..
14:1466-1475.
2015
-
Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs..
14:1087-1094.
2015
-
Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus..
14:1048-1056.
2015
-
Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78..
14:747-756.
2015
-
Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+..
14:70-79.
2015
-
Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response..
13:3219-3229.
2014
-
Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth..
13:1259-1269.
2014
-
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer..
12:2601-2613.
2013
-
PI3K stimulates DNA synthesis and cell-cycle progression via its p55PIK regulatory subunit interaction with PCNA..
12:2100-2109.
2013
-
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition..
12:1906-1917.
2013
-
A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth..
12:685-695.
2013
-
Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer..
11:1500-1509.
2012
-
XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells..
11:1518-1527.
2012
-
Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells..
11:1320-1331.
2012
-
Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance..
11:1214-1215.
2012
-
Starting with the ABCs: Akt in breast cancer..
10:2031.
2011
-
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors..
10:1367-1374.
2011
-
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells..
10:1137-1148.
2011
-
GPR54 is a target for suppression of metastasis in endometrial cancer..
10:580-590.
2011
-
Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells..
10:292-302.
2011
-
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy..
9:2090-2101.
2010
-
Effect of pazopanib on tumor microenvironment and liposome delivery..
9:1798-1808.
2010
-
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor..
9:1432-1442.
2010
-
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma..
9:779-790.
2010
-
Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA..
9:292-299.
2010
-
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program..
9:101-112.
2010
-
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme..
8:2773-2779.
2009
-
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts..
8:1751-1760.
2009
-
Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis..
8:1350-1362.
2009